PharmaTher selects PD Labs as US center of excellence for PERSONALIZ3D platform commercialization

• PharmaTher entered a collaboration agreement with PD Labs, naming it the U.S. Center of Excellence for PERSONALIZ3D.
• Move starts early commercialization of its telehealth-enabled personalized medicine and peptide platform using pharmaceutical 3D printing.
• PD Labs will support pharmacy fulfillment, help standardize workflows and quality controls, support patient-specific formulation development.
• Center in Cedar Park, Texas is expected to serve as the initial operating hub for a scalable U.S. pharmacy deployment model.
• Partnership is positioned as stage one of a three-step plan, ahead of a controlled U.S. telehealth commercial launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmather Holdings Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608180800NEWSFILECNPR____20260818_309951_1) on August 18, 2026, and is solely responsible for the information contained therein.